Publications by authors named "R De Lisi"
Article Synopsis
- A study analyzed 663 patients with transfusion-dependent β-thalassemia who received one of three iron chelation therapies (deferoxamine, deferiprone, or deferasirox) for up to 10 years, showing significant reductions in serum ferritin levels across all treatments.
- Despite these reductions, there were no notable changes in liver iron concentration or heart health indicators, as patients started with low levels of iron in these areas.
- While deferasirox was linked to better morbidity and mortality-free survival compared to deferoxamine, overall, the iron chelation effectiveness was similar among all three treatments in managing mild-to-moderate iron overload in patients.
Data on iron overload status and change thresholds that can predict mortality in patients with transfusion-dependent β-thalassemia (TDT) are limited. This was a retrospective cohort study of 912 TDT patients followed for up to 10 years at treatment centers in Italy (median age 32 years, 51.6% female).
View Article and Find Full Text PDFRate and risk factors for phenoconversion from non-transfusion-dependent β-thalassemia (NTDT) to transfusion-dependent β-thalassemia (TDT) during a 10-year follow up of adult patients in Italy.
View Article and Find Full Text PDF